Literature DB >> 15210597

Selective inhibition of protein kinase Cbeta2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells.

Alexei Kouroedov1, Masato Eto, Hana Joch, Massimo Volpe, Thomas F Lüscher, Francesco Cosentino.   

Abstract

BACKGROUND: Enhanced expression of adhesion molecules by the endothelium may account for vascular damage in diabetics and nondiabetic patients who develop stress hyperglycemia during acute myocardial infarction. We analyzed the phosphorylation of protein kinase Cbeta2 (PKCbeta2) at serine/threonine residues, which may contribute to the endothelial dysfunction during acute hyperglycemia. Furthermore, this study was designed to investigate whether selective blockade of this regulatory mechanism may prevent the development of endothelial hyperadhesiveness. METHODS AND
RESULTS: Incubation of the human aortic endothelial cells with high glucose (22.2 mmol/L) resulted in significant increase of vascular cell adhesion molecule (VCAM)-1 protein expression (172+/-15% versus control; P<0.01). Phorbol 12-myristate 13-acetate, a potent activator of PKC, mimicked the effect of high glucose on VCAM-1 expression. High glucose led to a rapid increase (181+/-22% versus control; P<0.01) of membrane-bound PKCbeta, reflecting activation of this enzyme. The nonselective inhibitor of PKCbeta1 and PKCbeta2 isoforms LY379196, as well as CGP53353, a highly selective inhibitor of PKCbeta2, prevented in a dose-dependent manner upregulation of VCAM-1. Incubation with high glucose was associated with increased PKCbeta2 phosphorylation at the Ser-660 residue, and both LY379196 and CGP53353 prevented this event. Exposure of the cells to high glucose also reduced the protein level of the inhibitory subunit of nuclear factor-kappaB, IkappaBalpha, leading to its enhanced binding activity. Selective inhibition of PKCbeta abolished IkappaBalpha degradation.
CONCLUSIONS: Our findings demonstrate for the first time that phosphorylation of Ser-660 represents a selective regulatory mechanism for glucose-induced upregulation of VCAM-1. Therefore, PKCbeta2-selective inhibitors may be promising drugs for treatment of endothelial dysfunction during acute hyperglycemia and possibly in diabetes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15210597     DOI: 10.1161/01.CIR.0000133384.38551.A8

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  34 in total

Review 1.  Therapeutic potential for protein kinase C inhibitor in vascular restenosis.

Authors:  Richard Qinxue Ding; Jerry Tsao; Hong Chai; Daria Mochly-Rosen; Wei Zhou
Journal:  J Cardiovasc Pharmacol Ther       Date:  2010-12-23       Impact factor: 2.457

Review 2.  Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications.

Authors:  Corey E Tabit; William B Chung; Naomi M Hamburg; Joseph A Vita
Journal:  Rev Endocr Metab Disord       Date:  2010-03       Impact factor: 6.514

3.  The beta-specific protein kinase C inhibitor ruboxistaurin (LY333531) suppresses glucose-induced adhesion of human monocytes to endothelial cells in vitro.

Authors:  Thomas Kunt; Thomas Forst; Christof Kazda; Oliver Harzer; Martin Engelbach; Mirjam Löbig; Jürgen Beyer; Andreas Pfützner
Journal:  J Diabetes Sci Technol       Date:  2007-11

Review 4.  Protein Kinase C as Regulator of Vascular Smooth Muscle Function and Potential Target in Vascular Disorders.

Authors:  H C Ringvold; R A Khalil
Journal:  Adv Pharmacol       Date:  2016-07-18

Review 5.  Pathogenesis of diabetic cerebral vascular disease complication.

Authors:  Ren-Shi Xu
Journal:  World J Diabetes       Date:  2015-02-15

6.  Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease.

Authors:  Christian Besler; Kathrin Heinrich; Lucia Rohrer; Carola Doerries; Meliana Riwanto; Diana M Shih; Angeliki Chroni; Keiko Yonekawa; Sokrates Stein; Nicola Schaefer; Maja Mueller; Alexander Akhmedov; Georgios Daniil; Costantina Manes; Christian Templin; Christophe Wyss; Willibald Maier; Felix C Tanner; Christian M Matter; Roberto Corti; Clement Furlong; Aldons J Lusis; Arnold von Eckardstein; Alan M Fogelman; Thomas F Lüscher; Ulf Landmesser
Journal:  J Clin Invest       Date:  2011-06-23       Impact factor: 14.808

7.  Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells.

Authors:  Yoshiyuki Rikitake; James K Liao
Journal:  Circulation       Date:  2005-06-13       Impact factor: 29.690

8.  Macrophage differentiation increases expression of the ascorbate transporter (SVCT2).

Authors:  Huan Qiao; James M May
Journal:  Free Radic Biol Med       Date:  2009-02-27       Impact factor: 7.376

9.  Protein kinase C-β contributes to impaired endothelial insulin signaling in humans with diabetes mellitus.

Authors:  Corey E Tabit; Sherene M Shenouda; Monica Holbrook; Jessica L Fetterman; Soroosh Kiani; Alissa A Frame; Matthew A Kluge; Aaron Held; Mustali M Dohadwala; Noyan Gokce; Melissa G Farb; James Rosenzweig; Neil Ruderman; Joseph A Vita; Naomi M Hamburg
Journal:  Circulation       Date:  2012-11-30       Impact factor: 29.690

10.  In Vivo Measurements of Tumor Metabolism and Growth after Administration of Enzastaurin Using Small Animal FDG Positron Emission Tomography.

Authors:  Karen E Pollok; Michael Lahn; Nathan Enas; Ann McNulty; Jeremy Graff; Shanbao Cai; Jennifer R Hartwell; Aaron Ernstberger; Donald Thornton; Les Brail; Gary Hutchins
Journal:  J Oncol       Date:  2009-05-27       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.